8-K: AnaptysBio Sues GSK/Tesaro Over Jemperli Rights

AnaptysBio has filed a lawsuit against TESARO and its parent GlaxoSmithKline, alleging material breaches of their collaboration agreement for the cancer drug dostarlimab (Jemperli) and seeking reversion of all rights.

Summary

• AnaptysBio filed a Verified Complaint in Delaware Chancery Court on November 20, 2025, against TESARO, Inc. and GlaxoSmithKline (GSK), alleging material breaches of their Collaboration and Exclusive License Agreement and tortious interference.
• The lawsuit centers on dostarlimab (Jemperli), a PD-1 antagonist, for which Tesaro was granted rights and obligated to use "commercially reasonable efforts" to obtain "optimum commercial return."
• AnaptysBio claims Tesaro/GSK violated exclusivity by developing or participating in trials with competitor PD-1s (e.g., Merck's Keytruda) and other Target Antagonists.
• Allegations include failure to disclose critical clinical trials, such as the I-SPY Trial, BEHOLD-2, and BEHOLD EC-02, and improper transfer of dostarlimab rights to GSK.
• AnaptysBio asserts that Tesaro/GSK prioritized GSK's antibody-drug conjugate (ADC) programs, conducting trials that benefit ADCs with competitor PD-1s, to dostarlimab's detriment.
• A previous dispute in 2020 over similar issues was settled with Tesaro/GSK paying AnaptysBio $60 million upfront, a royalty on Zejula sales, and more than doubling dostarlimab royalties (ranging from 8% to 25%).
• AnaptysBio seeks a court declaration that Tesaro materially breached the agreement, that the breaches are incurable, and that AnaptysBio is entitled to the reversion of all rights to dostarlimab.
• AnaptysBio also seeks damages for loss of competitive position, other economic losses, and attorneys' fees and costs.

Sentiment

Score: 3

Explanation: The filing details a significant legal dispute where AnaptysBio alleges its partner and its parent company have repeatedly breached a critical collaboration agreement, potentially undermining the commercial value of a key drug (dostarlimab) and AnaptysBio's associated royalty streams. While AnaptysBio is seeking to regain rights, the current situation involves active litigation and alleged detrimental actions by its partner, indicating a highly negative operational and financial environment for AnaptysBio regarding this asset.

Negatives

• Alleged material breaches of the Collaboration Agreement by Tesaro.
• Alleged tortious interference by GSK.
• Tesaro/GSK allegedly prioritizing competitor PD-1s and GSK's ADCs over dostarlimab, potentially harming its commercial return and AnaptysBio's royalty income.
• Failure to disclose critical clinical trials (I-SPY, BEHOLD-2, BEHOLD EC-02) as required by the agreement.
• Improper transfer of dostarlimab intellectual property rights to GSK, violating licensing restrictions.
• Potential loss of market position and future growth for dostarlimab due to alleged actions.
• The necessity of initiating a second lawsuit to enforce contractual rights, indicating a deeply fractured partnership.

Risks

• Uncertainty and significant costs associated with ongoing litigation against a major pharmaceutical company.
• Potential for continued harm to dostarlimab's commercial prospects if the alleged breaches are not remedied or if the court does not rule in AnaptysBio's favor.
• Risk of not regaining rights to dostarlimab, which would significantly impact AnaptysBio's future revenue streams from this asset.
• Reputational risk for AnaptysBio depending on the outcome and public perception of the lawsuit.
• Dependence on partners (Tesaro/GSK) for development and commercialization, which has proven problematic and led to repeated disputes.

Future Outlook

AnaptysBio seeks the reversion of all rights to dostarlimab, which would allow it to control the drug's future development and commercialization. The outcome of the ongoing lawsuit will significantly impact AnaptysBio's future revenue streams and strategic direction regarding this key asset. The BEHOLD EC-02 study, which is part of the dispute, is planned to start enrolling patients in Q1 2026.

Industry Context

The oncology market, particularly for PD-1 inhibitors and antibody-drug conjugates (ADCs), is highly competitive, with major players like Merck and AstraZeneca. Combination therapies are a critical strategy for maximizing drug efficacy and market share. This dispute highlights the complexities and potential conflicts of interest inherent in pharmaceutical collaboration agreements, especially following corporate acquisitions where the acquiring company (GSK) may prioritize its wholly-owned assets (GSK's ADCs) over licensed products (dostarlimab) if perceived conflicts arise. The allegations suggest a potential industry trend where large pharmaceutical companies may leverage their market power to the detriment of smaller partners' licensed assets.

Comparison to Industry Standards

• Merck and AstraZeneca design clinical trials to optimize the commercial return for two of their products in a combination therapy context, a practice AnaptysBio alleges Tesaro/GSK failed to follow for dostarlimab.
• Tesaro and GSK themselves have reportedly designed studies to optimize commercial return in other contexts not involving dostarlimab.
• Tesaro and GSK do not sponsor clinical trials with Zejula's competitors (e.g., Merck and AstraZeneca's Lynparza) because they understand it could hurt Zejula's optimum commercial return, a standard AnaptysBio claims was not applied to dostarlimab.
• Tesaro and GSK do not sponsor clinical trials with GSK's ADCs and competitor ADCs (e.g., Daiichi Sankyo and AstraZeneca's Enhertu and Datroway) because they know it could hurt GSK's ADCs optimum commercial return, further demonstrating an inconsistent application of diligence standards.
• AstraZeneca pursued a label for their CTLA-4 antagonist, Imjudo, which only allows it to be used together with their PD-1 antagonist, Imfinzi, to retain value.
• Bristol Myers Squibb sells their LAG-3 antagonist as a Fixed-Dose Combination (Opdualag) with their PD-1 antagonist (Opdivo) to prevent its use with competing PD-1s.
• Merck investigated only Keytruda for treatment of endometrial cancer in the TroFuse-033 study, combining one of Merck's ADCs with Keytruda without combining or comparing Keytruda to competing PD-1s, demonstrating methods to optimize value retention in combination products that AnaptysBio alleges Tesaro/GSK are not pursuing for dostarlimab.

Corporate Governance

Legal Proceedings

• AnaptysBio, Inc. filed a Verified Complaint in Delaware Chancery Court on November 20, 2025, against TESARO, Inc. and GlaxoSmithKline (GSK), alleging material breach of the Collaboration and Exclusive License Agreement by Tesaro and tortious interference by GSK.
• AnaptysBio seeks a court declaration that Tesaro materially breached the agreement, that the breaches are incurable, and that AnaptysBio is entitled to the reversion of all rights to dostarlimab.
• AnaptysBio also seeks all appropriate damages, including for loss of competitive position and other economic losses, and attorneys' fees and costs.
• Tesaro and GSK publicly filed their own complaint against AnaptysBio on November 26, 2025, claiming AnaptysBio breached the Collaboration Agreement (C.A. No. 2025-1357-KSJM (Del. Ch.)), indicating a countersuit.
• A previous lawsuit filed by AnaptysBio in August 2020 against Tesaro/GSK was settled on October 23, 2020, for $60 million upfront, Zejula royalties, and increased dostarlimab royalties.

Related Party Transactions

• The entire dispute revolves around the collaboration agreement between AnaptysBio and Tesaro, which became a wholly-owned subsidiary of GSK. GSK is alleged to control Tesaro's actions and finances, making the alleged breaches and interference effectively related-party dealings from AnaptysBio's perspective.
• AnaptysBio alleges Tesaro improperly assigned, licensed, or transferred dostarlimab intellectual property rights to GSK, violating Section 5.3(e) of the amended Collaboration Agreement.

Stakeholder Impact

• Shareholders (AnaptysBio): Face significant uncertainty due to litigation, with potential for substantial upside if rights revert, or downside if claims fail and dostarlimab's value is further eroded. Royalty income from dostarlimab is at risk.
• Shareholders (GSK/Tesaro): Face potential financial liability from damages and legal costs, and potential loss of rights to dostarlimab (Jemperli), an FDA-approved cancer therapy.
• Employees (AnaptysBio): Potential impact on future R&D and strategic direction depending on the outcome of the litigation and control over dostarlimab.
• Patients: Potential impact on the development and availability of dostarlimab, especially in combination therapies, depending on who controls its future.
• Creditors: Potential impact on AnaptysBio's financial health and ability to meet obligations if royalty streams are significantly affected.

Next Steps

• Ongoing legal proceedings in Delaware Chancery Court to resolve the dispute.
• AnaptysBio seeks a court declaration of material breach and tortious interference.
• AnaptysBio seeks the reversion of all rights to dostarlimab.
• AnaptysBio seeks monetary damages, including for loss of competitive position and other economic losses.
• The BEHOLD EC-02 study, which is a point of contention, is planned to start enrolling patients in Q1 2026.

Key Dates

Recommendation

The filing reveals a severe and ongoing legal dispute with a key partner (Tesaro/GSK) over a significant revenue-generating asset (dostarlimab). AnaptysBio alleges repeated and material breaches, including fraudulent concealment and actions detrimental to dostarlimab's commercial return. While AnaptysBio seeks reversion of rights, the immediate impact is high uncertainty, significant legal costs, and potential erosion of value for dostarlimab. The fact that this is a second lawsuit over similar issues indicates a deeply fractured relationship. Investors typically dislike such protracted legal battles, especially when they involve core assets and allegations of bad faith from a major pharmaceutical partner. The outcome is uncertain, and the current situation presents substantial downside risk to AnaptysBio's future revenue and asset control.

Keywords

AnaptysBio, ANAB, TESARO, GSK, GlaxoSmithKline, Jemperli, dostarlimab, PD-1 antagonist, cancer therapy, oncology, collaboration agreement, exclusive license, breach of contract, tortious interference, lawsuit, litigation, Delaware Chancery Court, antibody-drug conjugate, ADC, Keytruda, pembrolizumab, Zejula, niraparib, I-SPY Trial, BEHOLD EC-02, BEHOLD-2, commercial reasonable efforts, royalty payments, intellectual property